PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/aa8bdbeaeed88b5ebf160c2881f5ce7d.pdf

Abstract Title

First Name *

Radko

Last Name *

Komers

Co-author 1

Rosanna Coppo rosanna.coppo@unito.it Fondazione Ricerca Molinette, Regina Margherita Hospital N/A Turin

Co-author 2

Nuhira Ahmed Masthan Ahmed nuhira.masthan@travere.com Travere Therapeutics, Inc. Biostatistics San Diego

Co-author 3

Kenneth V. Lieberman kenneth.lieberman@hmhn.org Joseph M Sanzari Children's Hospital of the Hackensack Meridian Health Network Department of Pediatrics Division of Pediatric Nephrology Hackensack

Co-author 4

Alex Mercer alex.mercer@travere.com JAMCO Pharma Consulting N/A Stockholm

Co-author 5

Michelle Rheault rheau002@umn.edu University of Minnesota Medical School Division of Pediatric Nephrology Minneapolis

Co-author 6

Moin A. Saleem m.saleem@bristol.ac.uk University of Bristol & Bristol Royal Hospital for Children Bristol Renal Bristol

Co-author 7

Teresa Shafer teresa.shafer@travere.com Travere Therapeutics, Inc. Clinical Operations San Diego

Co-author 8

Howard Trachtman howardtrachtman21@gmail.com University of Michigan Department of Pediatrics, Division of Nephrology Ann Arbor

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15